A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Summary

This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. This study consists of 3 parts. Part A is focused on healthy participants. Parts B and C of the study are focused on participants who are known to have MASLD and a specific variant of the PNPLA3 gene. The aim of the study is to see how safe, tolerable and effective the study drug is.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Healthy Volunteers
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Regeneron Pharmaceuticals

Last updated on ClinicalTrials.gov

April 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites